Hepion Pharmaceuticals Announces Participation In The H.C. Wainwright BioConnect Conference

Published by
The Street

By GlobeNewswire EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (HEPA) – Get Hepion Pharmaceuticals, Inc. Report, a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. Hepion’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning …

Read More

See also  Speech Analytics Market Size, Share, Trends, Forecast 2021-26

Leave a Reply